Intravitreal Dexamethasone Implant Treatment in Patients With Diabetic Macular Edema Resistant to Anti-VEGF Treatment

Abstract

Purpose: To evaluate the efficacy and safety of intravitreal dexamethasone implant (IDI) (OZURDEX) in the patients with diabetic macular edema (DME) resistant to anti-VEGF treatment. Study Design: This retrospective study included 93 eyes of 93 patients who underwent IDI injection and changes in best corrected visual acuity (BCVA), central macular thickness (CMT), intraocular pressure (IOP) as well as presence of DME and ocular side effects were investigated. Results: Ninety three eyes of 93 patients (45 male, 48 female; the mean age was 67.32±10.68 years) were included. At least five monthly intravitreal ranibizumab (Lucentis) injections were administered before IDI and patients were considered to have resistant DME. A significant improvement was observed in BCVA while a significant decrease in CMT at all time points when compared to baseline (p